Skip to main content

Translational medicines ‘Ecosystem’

Section edited by Vijay Mahant

The Translational Medicines 'Ecosystem' section aims to provide a forum for the topics spanning the translational research ecosystem beyond academia. The section will include both research and opinions about the role of patients, government policies, healthcare providers, bio-industries such as biotechnology and pharmaceutical companies, regulatory agencies, ethics, payers, investors and academia in advancing novel medicines. Particular focus area will include opportunities and challenges in collaborating with industry and the role of stakeholders in the translational research “ecosystem”.

  1. Defining and protecting participants’ rights is the aim of several ethical codices and legal regulations. According to these regulations, the Informed Consent (IC) is an inevitable element of research with hum...

    Authors: Henriette Rau, Lars Geidel, Martin Bialke, Arne Blumentritt, Martin Langanke, Wenke Liedtke, Sandra Pasewald, Dana Stahl, Thomas Bahls, Christian Maier, Hans-Ulrich Prokosch and Wolfgang Hoffmann

    Citation: Journal of Translational Medicine 2020 18:287

    Content type: Research

    Published on:

  2. The “Right-to-Try” experimental drugs act passed by Donald Trump in 2018 provides an opportunity of early access to experimental drugs for the treatment of life-threatening diseases and a potential boon to man...

    Authors: Vijay Mahant

    Citation: Journal of Translational Medicine 2020 18:253

    Content type: Review

    Published on:

  3. This commentary presents the vision of the International Consortium for Personalised Medicine (ICPerMed) on how personalised medicine (PM) will lead to the next generation of healthcare by 2030. This vision fo...

    Authors: Astrid M. Vicente, Wolfgang Ballensiefen and Jan-Ingvar Jönsson

    Citation: Journal of Translational Medicine 2020 18:180

    Content type: Commentary

    Published on: